SCHEMBL10315754

SCHEMBL10315754

Cc1cc2nc(N3CCOCC3)nc(C(C)(C)C)c2cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
ATM Q13315 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
MAPT P10636 1/20 0.44
EHMT2 Q96KQ7 2/20 0.43
EHMT1 Q9H9B1 2/20 0.43
ALDH1A1 P00352 7/20 0.43
HPGD P15428 6/20 0.43
GAA P10253 5/20 0.43
KDM4E B2RXH2 5/20 0.43
HSD17B10 Q99714 4/20 0.43
MEN1 O00255 2/20 0.43
CASP1 P29466 2/20 0.43
CASP7 P55210 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43
STAT1 P42224 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13293269 0.83 EHMT2 (0.56) MAPTEHMT2EHMT1ALDH1A1HPGD
SCHEMBL14090659 0.79 KDM4E (0.63) MAPTALDH1A1HPGDGAAKDM4E
SCHEMBL31413447 0.78 ALDH1A1 (0.39) KMT2AATML3MBTL1TDP1MAPT
SCHEMBL25670607 0.70 KDM4E (0.35) ATML3MBTL1MAPTALDH1A1HPGD
SCHEMBL18997062 0.70 KDM4E (0.48) KMT2AALDH1A1KDM4EHSD17B10CASP1
SCHEMBL23634552 0.69 L3MBTL1 (0.60) KMT2AATML3MBTL1TDP1MAPT
SCHEMBL6626219 0.69 PIK3CB (0.66) KMT2AMAPTALDH1A1PIK3CAMTOR
SCHEMBL1707681 0.68 KMT2A (0.79) KMT2AMAPTALDH1A1HSD17B10MEN1
SCHEMBL31413390 0.68 ALDH3A1 (0.48) KMT2ATDP1MAPTALDH1A1MEN1
SCHEMBL6627718 0.67 PIK3CB (0.63) KMT2ATDP1MAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116169-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-09 US disclosed
US-8217048-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-10 US disclosed
US-20110104115-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE VERTEX PHARMACEUTICALS INCOROPRATED (US) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116169-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE SERPINB1, PRSS1, SPINT2 KMT2A 2411/4885ATM 3526/4885L3MBTL1 1764/4885
US-20110104115-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE SERPINB1, PRSS1, SPINT2 KMT2A 2411/4885ATM 3526/4885L3MBTL1 1764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.